SANUWAVE Health Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to Commission File Number 000-42552 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada20-1176000(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) (952) 656-1029(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Accelerated filerSmaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo As of May8, 2026, there were issued and outstanding 8,598,976 shares of the registrant’s common stock, $0.001 par value per share. SANUWAVE Health, Inc. Table of Contents Item 1.Financial Statements (Unaudited)4Condensed Consolidated Balance Sheets as of March 31, 2026, and December 31, 20254Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2026 and20255Condensed Consolidated Statements of Stockholders’Equity (Deficit)for the three months ended March 31,2026 and 20256Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20257Notes to Unaudited Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24PART II – OTHER INFORMATIONItem 1.Legal Proceedings25Item 1A.Risk Factors25Item 2.Unregistered Sales of Equity Securities and Use of Proceeds25Item 3.Defaults Upon Senior Securities25Item 4.Mine Safety Disclosures25Item 5.Other Information26Item 6.Exhibits26SIGNATURES28 Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q of SANUWAVE Health, Inc. and its subsidiaries (“Sanuwave,” the “Company,” “we,” “us,” and“our”) contains forward-looking statements. All statements in this Quarterly Report on Form 10-Q, including those made by themanagement of the Company, other than statements of historical fact, are forward-looking statements. Examples of forward-lookingstatements include, but are not limited to, statements regarding: results of operations, liquidity, and operations, restrictions and newregulations on our operations and processes, including the execution of clinical trials; the Company’s future financial results, operatingresults, and projected costs; market acceptance of and demand for UltraMIST®; the estimated size of the wound care market; successof future business development and acquisition activities; management’s plans and objectives for future operations; industry trends;regulatory actions that could adversely affect the price of or demand for our approved products; our intellectual property portfolio; ourbusiness, marketing and manufacturing capacity and strategy; estimates regarding our capital requirements, the anticipated timing ofthe need for additional funds, and our expectations regarding future capital-raising transactions, including through investments bystrategic partners for market opportunities, which may include strategic partnerships or licensing agreements, or raising capital throughthe issuances of securities; product liability claims; economic conditions that could adversely affect the level of demand for or the costof our products; timing of clinical studies and any eventual United S